Brokers Set Expectations for Pear Therapeutics, Inc.'s FY202

Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) – Research analysts at Chardan Capital boosted their FY2023 earnings per share estimates for shares of Pear Therapeutics in a report issued on Monday, April 3rd. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($0.56) for the year, up from […]

Related Keywords

Corey Mccann , Manufacturers Life Insurance Company , Pear Therapeutics Inc , Sg Americas Securities , Verdence Capital Advisors , Credit Suisse Group , Nasdaq , Pear Therapeutics Company Profile , Daiwa Securities Group Inc , Pear Therapeutics , Get Rating , Chardan Capital , Pear Therapeutic , Suisse Group , Securities Group , Capital Advisors , Pear Therapeutics Daily , Nasdaq Pear , Pear , Medical , Earnings Estimates ,